Market Overview

Why Cellectis Stock Is Trading Lower Today


Cellectis (NASDAQ: CLLS) shares are trading lower on Thursday after Baird downgraded the company's stock from Outperform to Neutral.

Cellectis is a biotechnology company focused on developing immunotherapies for cancer. The company engages in gene editing in an attempt to lead the body's immune system toward attacking cancer cells. Cellectis utilizes strategic corporate partnerships along with cooperation through various university clinical centers. The company's gene-editing technologies allow for the creation of healthy cells derived from healthy donors rather than the patients themselves.

Cellectis shares traded down 10.36% to $19.65 on Thursday. The stock has a 52-week high of $22.58 and a 52-week low of $7.32.

Latest Ratings for CLLS

Oct 2020BairdDowngradesOutperformNeutral
Aug 2020CitigroupUpgradesNeutralBuy
Jul 2020BairdMaintainsOutperform

View More Analyst Ratings for CLLS
View the Latest Analyst Ratings


Related Articles (CLLS)

View Comments and Join the Discussion!

Posted-In: why it's movingDowngrades Analyst Ratings

Latest Ratings

ZMRBC CapitalMaintains550.0
ZMJP MorganMaintains450.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at